The drive to remove the US company Palantir from the NHS in the UK ramped up in the last few weeks, with the release of a briefing by the health justice charity Medact. The report, backed by doctors, lawyers, patients and human rights groups from the No Palantir in the NHS campaign, including the Good Law Project, Privacy International, and Corporate Watch, and supported by Amnesty International, was sent to hospital trusts and integrated care boards nationwide.
The report urges NHS trusts and ICBs not to implement the Federated Data Platform (FDP) developed by Palantir, and for NHS England to terminate the contract. It notes that partnering with Palantir risks weakening patients’ trust while “driving out locally tailored and trusted data solutions”.
The briefing said the “highly interoperable nature” of Palantir’s software could enable “data-driven state abuses of power”, including US-style ICE raids.
In 2027, the initial three-year contract with Palantir is up for review, and at this point, NHS England could end the contract.
But what makes Palantir such a controversial partner for the NHS? How did it get its reputation?
Full article in The Lowdown, 31 March 2026
